贝伐珠单抗联合化疗治疗非鳞状细胞非小细胞肺癌的疗效观察

目的：观察贝伐珠单抗联合化疗治疗非鳞状细胞非小细胞肺癌的疗效和安全性.方法：回顾性分析2010年7月-2011年12月解放军总医院经组织病理学证实的局部进展或复发转移的非鳞状细胞非小细胞肺癌患者接受贝伐珠单抗联合化疗方案治疗的临床资料.贝伐珠单抗7.5mg/kg,每3周1次,联合多西他赛、培美曲塞或吉西他滨±铂类化疗.化疗2周期后按实体肿瘤疗效评价标准（RECIST）评价疗效,按美国癌症研究所制定的常见毒性判定标准（NCI-CTC） 3.0版评价不良反应.结果：21例患者中无完全缓解病例,部分缓解4例,稳定13例,进展4例,客观缓解率19.0％（4/21）,疾病控制率81.0％（17/21）,中位无疾病进展时间为7.0月,中位生存时间为10.4月.与贝伐珠单抗相关的不良反应出血6例（28.6％）,高血压1例（4.8％）,主要为Ⅰ、Ⅱ度,Ⅲ、Ⅳ度少见.结论：贝伐珠单抗联合化疗治疗进展或复发的非鳞状细胞非小细胞肺癌疗效确切,耐受性好.

Clinical observation of bevacizumab combined with chemotherapy in non-squamous non-small cell lung cancer patients

Objective：To evaluate the efficacy and safety of bevacizumab combined with chemotherapy in locally advanced or metastatic non-squamous non-small cell lung cancer （NSCLC） patients.Methods：Twenty-one locally advanced or metastatic non-squamous non-small cell lung cancer patients admitted to our hospital from July 2010 to December 2011 received bevacizumab （7.5 mg/kg every 3 weeks） combined with docetaxed,pemetrexed or gemcitabine and/or platinum.The efficacy was estimated by RICIST evaluation standard every 2 cycles and the toxicity was estimated by NCI CTC 3.0 Standard every cycle.Results：For a total of 21 patients,there was no case with complete response.4 cases had partial response,13 cases had stable disease and 4 cases had progressive disease.The objective response rate was 19.0％ （4/21）.The disease control rate was 81.0％ （17/21）.The mediantime for progressive disease was 7.0 months,and the median survival time was 10.4 months.The most commonly adverse events of bevacizumab were bleeding and hypertension,most were grade Ⅰ/Ⅱ and degree Ⅲ/Ⅳ were rare.Conclusion：Bevacizumab combined with chemotherapy is effective and tolerable for locally advanced or metastatic non-squamous NSCLC patients.